These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 19309222)

  • 1. Imatinib is a substrate for various multidrug resistance proteins.
    Czyzewski K; Styczynski J
    Neoplasma; 2009; 56(3):202-7. PubMed ID: 19309222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro.
    Ferrao PT; Frost MJ; Siah SP; Ashman LK
    Blood; 2003 Dec; 102(13):4499-503. PubMed ID: 12881321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib.
    Stromskaya TP; Rybalkina EY; Kruglov SS; Zabotina TN; Mechetner EB; Turkina AG; Stavrovskaya AA
    Biochemistry (Mosc); 2008 Jan; 73(1):29-37. PubMed ID: 18294126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1.
    Gromicho M; Dinis J; Magalhães M; Fernandes AR; Tavares P; Laires A; Rueff J; Rodrigues AS
    Leuk Lymphoma; 2011 Oct; 52(10):1980-90. PubMed ID: 21663515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells.
    Peng XX; Tiwari AK; Wu HC; Chen ZS
    Chin J Cancer; 2012 Feb; 31(2):110-8. PubMed ID: 22098951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells.
    Mukai M; Che XF; Furukawa T; Sumizawa T; Aoki S; Ren XQ; Haraguchi M; Sugimoto Y; Kobayashi M; Takamatsu H; Akiyama S
    Cancer Sci; 2003 Jun; 94(6):557-63. PubMed ID: 12824882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
    Tsimberidou AM; Paterakis G; Androutsos G; Anagnostopoulos N; Galanopoulos A; Kalmantis T; Meletis J; Rombos Y; Sagriotis A; Symeonidis A; Tiniakou M; Zoumbos N; Yataganas X
    Leuk Res; 2002 Feb; 26(2):143-54. PubMed ID: 11755464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.
    Mahon FX; Belloc F; Lagarde V; Chollet C; Moreau-Gaudry F; Reiffers J; Goldman JM; Melo JV
    Blood; 2003 Mar; 101(6):2368-73. PubMed ID: 12609962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of imatinib and 5-bromotetrandrine on the reversal of multidrug resistance of the K562/A02 cell line.
    Chen BA; Shan XY; Chen J; Xia GH; Xu WL; Schmit M
    Chin J Cancer; 2010 Jun; 29(6):591-5. PubMed ID: 20507731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
    Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
    Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib.
    Gromicho M; Magalhães M; Torres F; Dinis J; Fernandes AR; Rendeiro P; Tavares P; Laires A; Rueff J; Sebastião Rodrigues A
    Oncol Rep; 2013 Feb; 29(2):741-50. PubMed ID: 23229016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Establishment of an imatinib resistant cell line K562/G01 and its characterization].
    Qi J; Peng H; Gu ZL; Liang ZQ; Yang CZ
    Zhonghua Xue Ye Xue Za Zhi; 2004 Jun; 25(6):337-41. PubMed ID: 15308010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.
    La Rosée P; Johnson K; O'Dwyer ME; Druker BJ
    Exp Hematol; 2002 Jul; 30(7):729-37. PubMed ID: 12135670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells.
    Silva KL; de Souza PS; Nestal de Moraes G; Moellmann-Coelho A; Vasconcelos Fda C; Maia RC
    Leuk Res; 2013 Oct; 37(10):1350-8. PubMed ID: 23891189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?
    Broxterman HJ; Sonneveld P; Pieters R; Lankelma J; Eekman CA; Loonen AH; Schoester M; Ossenkoppele GJ; Löwenberg B; Pinedo HM; Schuurhuis GJ
    Leukemia; 1999 Feb; 13(2):258-65. PubMed ID: 10025900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statins inhibit ABCB1 and ABCG2 drug transporter activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib.
    Glodkowska-Mrowka E; Mrowka P; Basak GW; Niesiobedzka-Krezel J; Seferynska I; Wlodarski PK; Jakobisiak M; Stoklosa T
    Exp Hematol; 2014 Jun; 42(6):439-47. PubMed ID: 24667683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells.
    Michieli M; Damiani D; Ermacora A; Raspadori D; Michelutti A; Grimaz S; Fanin R; Russo D; Lauria F; Masolini P; Baccarani M
    Br J Haematol; 1997 Feb; 96(2):356-65. PubMed ID: 9029025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.
    Hiwase DK; Saunders V; Hewett D; Frede A; Zrim S; Dang P; Eadie L; To LB; Melo J; Kumar S; Hughes TP; White DL
    Clin Cancer Res; 2008 Jun; 14(12):3881-8. PubMed ID: 18559609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukaemia.
    Michieli M; Damiani D; Ermacora A; Geromin A; Michelutti A; Masolini P; Baccarani M
    Br J Haematol; 2000 Mar; 108(4):703-9. PubMed ID: 10792272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib.
    Hatziieremia S; Jordanides NE; Holyoake TL; Mountford JC; Jørgensen HG
    Exp Hematol; 2009 Jun; 37(6):692-700. PubMed ID: 19394750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.